title: Prognostic factors for patients with spinal metastases from lung cancer.
abstract: METHODS
  We conducted a retrospective study to identify prognostic factors of patients with spinal metastases from lung cancer.
  
  
  OBJECTIVE
  To provide clinical data with strong association to the prognosis and to propose criteria determining indication of operation for spinal metastases.
  
  
  BACKGROUND
  To make a proper selection of patients for whom surgery is indicated, forecasting short-time survival after spinal metastases is very important. In the past, there has been no report of prognostic factors of patients with such metastases from this cancer.
  
  
  METHODS
  This study included 114 patients with spinal metastases of lung cancer. Tumors were histologically categorized as non-small cell lung cancer (NSCLC) in 94 patients and small cell lung cancer (SCLC) in 20 patients. We investigated prognostic factors after spinal metastases using Cox comparative hazard model and a preoperative prognostic score proposed by Tokuhashi. We also investigated the patients who underwent operation for spinal metastases from lung cancer in our hospital.
  
  
  RESULTS
  Multivariate analysis showed that the significant prognostic factors for survival after spinal metastases from NSCLC were performance status (PS), Ca, Alb. Among SCLC patients, Ca, Alb, and a history of chemotherapy were significant (P < 0.05) in univariate analysis. The score of Tokuhashi was not correlative to the survival period. Among the operated patients, postoperative PS was significant for the period of postoperative survival.
  
  
  CONCLUSIONS
  PS, Ca, and Alb in NSCLC and Ca, Alb, and a history of chemotherapy in SCLC are useful for determining an indication of operation for spinal metastases from lung cancer.
authors.affiliation: Department of Orthopaedic Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ogihara
authors.forename: Atsushi
authors.initials: A
authors.lastname: Seichi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Hozumi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Oka
authors.forename: Ryuuji
authors.initials: R
authors.lastname: Ieki
authors.forename: Kozo
authors.initials: K
authors.lastname: Nakamura
authors.forename: Taiji
authors.initials: T
authors.lastname: Kondoh
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002118:Calcium / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000503:physiopathology / Q000556:secondary* / Q000601:surgery*; D018288:Carcinoma, Small Cell / Q000150:complications / Q000503:physiopathology / Q000556:secondary* / Q000601:surgery*; D005260:Female; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010243:Paralysis / Q000453:epidemiology / Q000209:etiology; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012709:Serum Albumin / Q000378:metabolism; D013118:Spinal Cord Diseases / Q000453:epidemiology / Q000209:etiology; D013125:Spinal Neoplasms / Q000150:complications / Q000503:physiopathology / Q000556:secondary* / Q000601:surgery*; D016019:Survival Analysis
chemical_list: D012709:Serum Albumin; D002118:Calcium